Preparing For Tivozanib Approval, Aveo Restructures With Staff Cuts
This article was originally published in The Pink Sheet Daily
Executive Summary
The Cambridge, Mass.-based company slows R&D and lays off 17% of its work force, but prepares to build a sales staff as it continues to reap auspicious data on the kidney cancer drug.